EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A narrative review on preclinical/clinical trials on aducanumab

Akriti Goel, G Garima, Paras Jain, Seema Bansal, Hitesh Chopra, Sumeet Gupta, Satish Kumar, Meenakshi Dhanawat, Navidha Aggarwal

Scripta Medica · 2026 · 57 (2) · 371-388

DOI: 10.5937/scriptamed57-59386 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Scripta Medica, 2026. Verfasst von Akriti Goel und 8 weiteren Autor:innen. Die Arbeit nennt 87 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The most widespread type of dementia, Alzheimer's disease (AD), is predicted to triple in global prevalence by 2050. AD has a substantial societal and economic impact across the world, negatively affecting both patients and their caregivers, as the disorder has few therapeutic alternatives. Aducanumab was the first monoclonal antibody approved in 2021 for the treatment of mild AD. Representing the first AD drug approval in 20 years and based on the concept of targeting amyloid-β (Aβ) as an immunisation treatment for AD, aducanumab was demonstrated to reduce Aβ plaque formation in animal models and humans. This was used as a proxy of efficacy in AD clinical trials to slow disease progression and reduce cognitive decline in AD. Culminating from the Aβ hypothesis of AD that has dominated the focus of AD drug development since its inception, aducanumab, for many, represents validation of the hypothesis and promise for the future. This review examines the antibody research, preclinical and clinical studies, that underpin the development of aducanumab as an AD medication. No single drug is generally likely to cure a complex, progressive and heterogeneous degenerative disorder, but it may act as a stepping stone towards greater understanding and potentially more effective treatment options. Time will ultimately tell in the case of aducanumab as to whether it is a small or large step in the correct or incorrect direction to unravel the mystery of this complex disorder and provide a worthwhile treatment.

Förderung

  • This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors

Zitieren

APA

Goel, A., Garima, G., Jain, P., Bansal, S., Chopra, H., Gupta, S., Kumar, S., Dhanawat, M., & Aggarwal, N. (2026). A narrative review on preclinical/clinical trials on aducanumab. Scripta Medica, 57(2), 371-388. https://doi.org/10.5937/scriptamed57-59386

Vancouver

Goel A, Garima G, Jain P, Bansal S, Chopra H, Gupta S, et al. A narrative review on preclinical/clinical trials on aducanumab. Scripta Medica. 2026;57(2):371-388. doi:10.5937/scriptamed57-59386

BibTeX
@article{Goel2026,
  author = {Goel, Akriti and Garima, G and Jain, Paras and Bansal, Seema and Chopra, Hitesh and Gupta, Sumeet and Kumar, Satish and Dhanawat, Meenakshi and Aggarwal, Navidha},
  title = {A narrative review on preclinical/clinical trials on aducanumab},
  journal = {Scripta Medica},
  year = {2026},
  volume = {57},
  number = {2},
  pages = {371--388},
  doi = {10.5937/scriptamed57-59386}
}
Kostenlos starten →